PMG Research has Been Acquired by ICON

Tuesday, December 15, 2015

PMG Research has Been Acquired by ICON

William Blair acted as financial advisor to PMG Research, Inc., a portfolio company of Frontier Capital, in connection with its sale to Dublin, Ireland-based ICON plc (Nasdaq: ICLR). The transaction closed on December 4, 2015.

Transaction Highlights

  • Deep relationships and sector expertise: PMG Research and Frontier Capital were attracted to William Blair’s highly relevant transaction experience, deep pharma services and contract research organization (CRO) sector knowledge, and ability to identify and effectively engage with strategic acquirers globally. Highlighting the company’s innovative approach relative to the traditional clinical research site model, exceptional management team, and compelling growth trajectory were critical to driving value.
  • Process and execution excellence: William Blair’s transaction team marketed PMG Research to a targeted group of strategic buyers creating a strong competitive tension and robust value in this cross-border transaction.
  • Trusted guidance: William Blair worked closely with PMG Research’s management team to identify key investment highlights and growth opportunities and was a trusted advisor throughout each stage of the sale process. Hands-on involvement and effective communication from the William Blair team resulted in an outstanding outcome for Frontier Capital and PMG Research’s other shareholders. This transaction marks William Blair’s second successful outcome for Frontier Capital.

About the Companies

PMG Research, Inc. is an integrated network of clinical research facilities with 12 hub sites. PMG has conducted more than 7,500 research studies for hundreds of pharmaceutical sponsors and CROs since 1979. The company has extensive experience conducting all phases of trials across a comprehensive list of conditions.

ICON plc is a global provider of drug development solutions and services to the pharmaceutical, biotechnology, and medical device industries. The company specializes in the strategic development, management and analysis of programs that support clinical development—from compound selection to Phase I-IV clinical studies. Based in Dublin, Ireland, ICON currently operates from 77 locations in 38 countries and has approximately 11,700 employees.

News Alerts

Stay connected to your favorite publications and news features.

Subscribe Now